Jemila Houacine

Jemila Houacine

Auto-generated profile, based on publicly available information

Jemila Houacine

Alderaan Biotechnology, Paris, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
SFStéphane Fattori
Stéphane Fattori
ARAude Le Roy
Aude Le Roy
JHJemila Houacine
Jemila Houacine
LRLucie Robert
Lucie Robert
RARiad Abes
Riad Abes
DODaniel Olive
Daniel Olive
Regulatory T cells (Treg) impede effective antitumor immunity. However, the role of Tregs in the clinical outcomes of patients with triple-negative breast cancer (TNBC) remains controversial. Here, we found that an immunosuppressive TNBC microenvironment is marked by an imbalance between effector αβCD8+ T cells and Tregs harboring hallmarks of highly suppressive effector Tregs (eTreg). Intratumoral eTregs strongly expressed PD-1 and persisted in patients with TNBC resistant to PD-1 blockade. Importantly, CD25 was the most selective surface marker of eTregs in primary TNBC and metastases compared with other candidate targets for eTreg depletion currently being evaluated in trials for patients with advanced TNBC. In a syngeneic TNBC model, the use of Fc-optimized, IL2 sparing, anti-CD25 antibodies synergized with PD-1 blockade to promote systemic antitumor immunity and durable tumor growth control by increasing effector αβCD8+ T-cell/Treg ratios in tumors and in the periphery. Together, this study provides the rationale for the clinical translation of anti-CD25 therapy to improve PD-1 blockade responses in patients with TNBC. Significance: An imbalance between effector CD8+ T cells and CD25high effector Tregs marks immunosuppressive microenvironments in αPD-1–resistant TNBC and can be reversed through effector Treg depletion to increase αPD-1 efficacy.

30 August 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SFStephane Fattori
Stephane Fattori
HRHugo Roux
Hugo Roux
ECEmilie Connen
Emilie Connen
LRLucie Robert
Lucie Robert
Laurent GorvelLaurent Gorvel
Laurent Gorvel
DODaniel Olive
Daniel Olive
Regulatory T cells (Treg) are an immunosuppressive subtype of CD4+ T cells essential for maintaining self-tolerance in physiological settings. Tregs also abundantly infiltrate inflamed tumor tissues, impeding the host's antitumor immune response and contributing to tumor growth and metastasis. In breast cancers, subsets of Tregs express highly immunosuppressive effector phenotypes that favor tumorigenesis, progression, and resistance to immune-checkpoint inhibitor therapies. Tregs share phenotypic features with cytotoxic lymphocytes, rendering them difficult to inhibit without compromising productive antitumor immunity. In addition, systemic targeting of Tregs causes serious autoimmune adverse events in patients with cancer. Hence, the identification of candidate targets or methodologies allowing the specific elimination of tumor antigen-specific Tregs, including tumor-infiltrating Tregs, is a prerequisite for developing efficient and safe combinatorial immunotherapeutic strategies in breast cancers. To date, numerous preclinical studies have demonstrated that specific targeting of breast tumor–infiltrating Tregs restores a competent antitumor immune response and improves responses to immune-checkpoint inhibitors such as PD-1/PD-L1 blockade. Herein, we discuss major candidate molecules for Treg-targeted therapeutic strategies in breast cancers, detailing the pros and cons of various approaches, including mAb-mediated depletion, homeostasis destabilization, and functional blockade.

24 November 2025
Verified
Other
Open access
SFStéphane Fattori
Stéphane Fattori
ARAude Le Roy
Aude Le Roy
JHJemila Houacine
Jemila Houacine
LRLucie Robert
Lucie Robert
RARiad Abes
Riad Abes
DODaniel Olive
Daniel Olive
Differentially expressed genes between pre-αPD-1 Tregs versus post-αPD-1 Tregs, related to Figure 4

24 November 2025
Verified
Other
Open access
SFStéphane Fattori
Stéphane Fattori
ARAude Le Roy
Aude Le Roy
JHJemila Houacine
Jemila Houacine
LRLucie Robert
Lucie Robert
RARiad Abes
Riad Abes
DODaniel Olive
Daniel Olive
Clinical characteristics of patients with breast cancer

24 November 2025
Verified
Other
Open access
SFStéphane Fattori
Stéphane Fattori
ARAude Le Roy
Aude Le Roy
JHJemila Houacine
Jemila Houacine
LRLucie Robert
Lucie Robert
RARiad Abes
Riad Abes
DODaniel Olive
Daniel Olive
Percentage of immune cell types in primary TNBC, related to Figure 2

24 November 2025
Verified
Other
Open access
SFStéphane Fattori
Stéphane Fattori
ARAude Le Roy
Aude Le Roy
JHJemila Houacine
Jemila Houacine
LRLucie Robert
Lucie Robert
RARiad Abes
Riad Abes
DODaniel Olive
Daniel Olive
CDC_monocyte_macrophage subpopulations gene features, related to Figure 1